Key Points
- Kerry Wentworth, a Nuvation Bio insider, sold 36,750 shares on April 17 at an average price of $5.01 under a pre-arranged Rule 10b5-1 plan—reducing her stake by about 40.95% to 53,000 shares; she also sold 200,000 shares on April 6 at $4.52.
- Nuvation Bio, a clinical-stage biotech with a market cap near $1.78 billion, reported Q1 EPS of ($0.11) on $41.87 million revenue and a deeply negative net margin, while analysts hold a consensus "Moderate Buy" rating with a $11.63 target price.
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Kerry Wentworth sold 36,750 shares of the company's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.01, for a total transaction of $184,117.50. Following the completion of the sale, the insider directly owned 53,000 shares of the company's stock, valued at approximately $265,530. This trade represents a 40.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kerry Wentworth also recently made the following trade(s):
- On Monday, April 6th, Kerry Wentworth sold 200,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.52, for a total transaction of $904,000.00.
Nuvation Bio Stock Performance
NUVB stock opened at $5.13 on Wednesday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -8.54 and a beta of 1.60. The firm has a 50-day simple moving average of $4.86 and a two-hundred day simple moving average of $5.87. Nuvation Bio Inc. has a one year low of $1.57 and a one year high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95.
Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). The business had revenue of $41.87 million during the quarter, compared to analyst estimates of $36.82 million. Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. On average, equities analysts forecast that Nuvation Bio Inc. will post -0.47 EPS for the current fiscal year.
Hedge Funds Weigh In On Nuvation Bio
Several hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in Nuvation Bio by 41.4% in the 1st quarter. SG Americas Securities LLC now owns 87,387 shares of the company's stock worth $375,000 after buying an additional 25,596 shares during the period. Corient Private Wealth LLC acquired a new position in Nuvation Bio in the 4th quarter worth approximately $2,277,000. Invesco Ltd. increased its holdings in Nuvation Bio by 138.2% in the 4th quarter. Invesco Ltd. now owns 1,185,143 shares of the company's stock worth $10,619,000 after buying an additional 687,597 shares during the period. Beacon Pointe Advisors LLC increased its holdings in Nuvation Bio by 60.4% in the 4th quarter. Beacon Pointe Advisors LLC now owns 259,212 shares of the company's stock worth $2,323,000 after buying an additional 97,612 shares during the period. Finally, NewEdge Advisors LLC acquired a new position in Nuvation Bio in the 4th quarter worth approximately $8,531,000. Institutional investors and hedge funds own 61.67% of the company's stock.
Analyst Ratings Changes
Several analysts have commented on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. UBS Group cut their price objective on shares of Nuvation Bio from $10.00 to $7.00 and set a "neutral" rating on the stock in a report on Tuesday, March 3rd. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Thursday, April 16th. Truist Financial set a $13.00 price objective on shares of Nuvation Bio in a report on Tuesday, January 27th. Finally, HC Wainwright cut their price objective on shares of Nuvation Bio from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, January 12th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $11.63.
Check Out Our Latest Research Report on Nuvation Bio
About Nuvation Bio
(
Get Free Report)
Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.
The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
